Sandipkumar S. Kapadia
Finanzdirektor/CFO bei HARMONY BIOSCIENCES HOLDINGS, INC.
Vermögen: - $ am 31.05.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Patrick Amstutz | M | 49 |
Molecular Partners, Inc.
 Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 20 Jahre |
| Stephen P. Squinto | M | 67 |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 6 Jahre |
| Michael Tobias Stumpp | M | 52 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 20 Jahre |
| Thomas Woiwode | M | 52 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 6 Jahre |
| Jeffrey Dayno | M | 66 | 7 Jahre | |
| William Burns | M | 76 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 7 Jahre |
| Jerome B. Durso | M | 56 | 7 Jahre | |
| Edgar Cale | M | 60 | 5 Jahre | |
| Chahra Khaoua Epouse Louafi | F | 53 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 Jahre |
| Paul Carter | M | 63 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 3 Jahre |
| Johannes G. C. P. Schikan | M | 66 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 Jahre |
| Michael Vasconcelles | M | 61 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 4 Jahre |
| William Chou | M | 51 | 2 Jahre | |
| Murray Stewart | M | 63 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 3 Jahre |
| Vito Palombella | M | 61 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 4 Jahre |
| Luca Santarelli | M | 55 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 Jahre |
| Steven Holtzman | M | 70 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 10 Jahre |
| Maxine Gowen | M | 66 | 3 Jahre | |
| Linda Szyper | F | 58 | 3 Jahre | |
| James M. Wilson | M | - | 7 Jahre | |
| Derrell Porter | M | 53 | 3 Jahre | |
| Jeffrey Aronin | M | 56 | 7 Jahre | |
| Jared M. Freedberg | M | 55 | 3 Jahre | |
| Daniel Steiner | M | - | 13 Jahre | |
| Lisa Bright | F | 56 |
Intercept Pharma Europe Ltd.
 Intercept Pharma Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2014, Intercept Pharma Europe Ltd. is a subsidiary of Intercept Pharmaceuticals, Inc. that researches, develops, and sells pharmaceutical products. The company is based in Bristol, UK. | 10 Jahre |
| Jeffrey Dierks | M | 52 | 7 Jahre | |
| Ulrich Christian | M | - | 3 Jahre | |
| Sharon Goldbach | F | - | - | |
| Dominik Höchli | M | 57 | 3 Jahre | |
| Kathleen Borthwick | F | 48 | 3 Jahre | |
| Daniel Carey Cazel Hood | M | 51 |
Intercept Pharma Europe Ltd.
Intercept Pharma Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2014, Intercept Pharma Europe Ltd. is a subsidiary of Intercept Pharmaceuticals, Inc. that researches, develops, and sells pharmaceutical products. The company is based in Bristol, UK. | - |
| Kumar Budur | M | 53 | - | |
| R. Graf | M | 59 | 4 Jahre | |
| Athena Countouriotis | M | 52 | 4 Jahre | |
| Stuart M. Henderson | M | - | 3 Jahre | |
| Saqib Islam | M | 54 | 5 Jahre | |
| Jack Nielsen | M | 60 | 7 Jahre | |
| Andreas Wicki | M | 64 | 7 Jahre | |
| Seth D. Lewis | M | - | 5 Jahre | |
| Agnete Brunsvik Fredriksen | M | 47 | 3 Jahre | |
| Juan Sabater | M | 59 | 7 Jahre | |
| Gwen A. Fyfe | M | 72 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 5 Jahre |
| Andreas Emmenegger | M | 58 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 17 Jahre |
| Gary Sender | M | 62 | 4 Jahre | |
| Peter Anastasiou | M | 53 | 1 Jahre | |
| Antonio Gracias | M | 53 | 7 Jahre | |
| Renate Gloggner | F | - | 3 Jahre | |
| Cate McCanless | F | - | - | |
| Michael Pitzner | M | - | 2 Jahre | |
| Philippe Legenne | M | - | 4 Jahre | |
| Luis Sanay | M | - | 2 Jahre | |
| Alexander Zürcher | M | - | 2 Jahre | |
| Dolan Sondhi | M | 53 | 1 Jahre | |
| Mark Forman | M | 60 | 3 Jahre | |
| Andrew Serafin | M | 49 | 7 Jahre | |
| Audrey Murphy | F | - | - | |
| Andrea Campanile | F | - | - | |
| Brant Schofield | M | - |
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | 8 Jahre |
| Linda M. Richardson | F | 60 | 6 Jahre | |
| Christian Meyer | M | 56 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | - |
| Mark Pruzanski | M | 56 |
Intercept Pharma Europe Ltd.
Intercept Pharma Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2014, Intercept Pharma Europe Ltd. is a subsidiary of Intercept Pharmaceuticals, Inc. that researches, develops, and sells pharmaceutical products. The company is based in Bristol, UK. | - |
| Baris Arican | M | - | 2 Jahre | |
| Alex Fotopoulos | M | 55 | 5 Jahre | |
| Tricia Glover | F | - | - | |
| David Bradshaw | M | 62 | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Bruce Goldsmith | M | 58 | 2 Jahre | |
| John Jacobs | M | 57 | 6 Jahre | |
| Jonathan Silverstein | M | 57 | 7 Jahre | |
| Klaus Veitinger | M | 62 | 4 Jahre | |
| Wouter Joustra | M | 35 | 1 Jahre | |
| Bryan Ball | M | 54 | 1 Jahre | |
| Bryan Yoon | M | 46 | 4 Jahre | |
| Nancy Miller-Rich | F | 65 | 5 Jahre | |
| Eric L. Motley | M | 51 | 1 Jahre | |
| Michael Kamarck | M | 73 | 1 Jahre | |
| Mark Vignola | M | 47 | 4 Jahre | |
| Keith Gottesdiener | M | 70 | 7 Jahre | |
| Scott Applebaum | M | 57 | - | |
| Liam Ratcliffe | M | 60 | 3 Jahre | |
| Patrick Heron | M | 53 | 3 Jahre | |
| Daniel Bradbury | M | 62 | 7 Jahre | |
| Tadataka Yamada | M | 78 | 4 Jahre | |
| Ryan Sullivan | M | 48 | 2 Jahre | |
| Patrick Malloy | M | - | - | |
| Göran Albert Ando | M | 75 | 10 Jahre | |
| Nicolas Leupin | M | 50 | 4 Jahre | |
| David Ford | M | 56 | 6 Jahre | |
| Jill Quigley | F | 49 | 3 Jahre | |
| Desiree Luthman | M | 65 | 3 Jahre | |
| Eliseo Salinas | M | 69 | 1 Jahre | |
| Simona King | F | 52 | 2 Jahre | |
| Omar Khwaja | M | 54 | - | |
| William Lee | M | 69 | 13 Jahre | |
| Jason A. Campagna | M | 54 | 2 Jahre | |
| Gary Romano | M | 63 | 2 Jahre | |
| Gwendolyn Fisher | F | - | 2 Jahre | |
| Susan Drexler | F | 54 | 2 Jahre | |
| Brian Burkavage | M | - | 1 Jahre | |
| Monika Tornsen | F | 45 | 1 Jahre | |
| Rachel McMinn | M | 51 | 3 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 76 | 76,00% |
| Schweiz | 32 | 32,00% |
| Vereinigtes Königreich | 3 | 3,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Sandipkumar S. Kapadia
- Persönliches Netzwerk
